CK‑MM stands for creatine kinase muscle‑type (MM) isoenzyme. It’s the predominant creatine kinase isoform in skeletal muscle (and present to a lesser extent in heart), catalyzing the reversible transfer of a phosphate between ATP and creatine. Elevated CK‑MM levels in blood typically indicate skeletal muscle injury, strenuous exercise, myopathies, or other conditions causing muscle cell damage.

High CK‑MM levels indicate skeletal muscle injury or stress. Common causes include acute trauma, vigorous exercise, rhabdomyolysis, crush injuries, inflammatory myopathies (polymyositis, dermatomyositis), muscular dystrophies, intramuscular injections, seizures, prolonged immobility, hypothyroidism, alcohol or drug toxicity (e.g., statins), and infections. Levels rise after surgery or muscle ischemia and merit evaluation for underlying muscle damage.

CK-MM and CK-MB are creatine kinase isoenzymes made of M and B subunits. CK-MM is the predominant form in skeletal muscle (also present in heart), so elevations usually reflect skeletal muscle injury or exercise. CK-MB is enriched in cardiac muscle and is more specific for myocardial injury; clinicians use CK-MB levels and timing of rise/fall to help diagnose acute myocardial infarction.

When CK‑MM is high, it indicates damage or increased permeability of skeletal muscle cells releasing the muscle‑specific creatine kinase isoform into blood. Causes include strenuous exercise, trauma, injections, inflammatory myopathies, muscular dystrophies, seizures, drugs (e.g., statins), or rhabdomyolysis. Very high levels risk kidney injury. Interpretation requires clinical context, repeat testing, and evaluation of symptoms, urine myoglobin, and kidney function.

Low CK‑MM reflects reduced skeletal muscle enzyme rather than primary disease. Common causes include low muscle mass (aging, cachexia), prolonged immobility or disuse atrophy, and late-stage muscular dystrophies when muscle is replaced by fat/fibrosis. Some medications (long‑term corticosteroids), genetic variation and physiological states (pregnancy) can lower CK‑MM. Laboratory or sample‑handling issues may also give falsely low results.

Cancers that can raise creatine kinase include primary muscle tumors (rhabdomyosarcoma) and cancers that trigger paraneoplastic inflammatory myositis, notably lung (including small‑cell), breast, ovarian, gastrointestinal and colorectal cancers. Lymphoma and leukemia may raise CK with muscle involvement. Direct metastatic invasion of muscle and some cancer treatments (for example immunotherapy or certain chemotherapies) can also elevate CK.